Share

Chantal Quinten of the EORTC Quality of Life Department receives the 2010 ISOQOL Young Investigator Award

Each year the International Society for Quality of Life (ISOQOL) recognizes the best presentations made by investigators in the early stages of their career in QOL research. This year, during its annual conference held on 30 October 2010 in London, Chantal Quinten of the EORTC Quality of Life Department received the Young Investigator Award for her research entitled: “Investigating heterogeneity for survival in a pooled cancer cohort of closed EORTC Randomized Controlled Trials”.[1]

Chantal, together with her colleagues from the EORTC Quality of Life PROBE (Patient Reported Outcomes and Behavioral Evidence) team (www.eortc.be/probe), investigated in a pooled dataset of closed EORTC clinical studies, the prognostic value of clinical and health related quality of life (HRQOL) variables for survival taking into account heterogeneity in survival across the different cancer sites included in that dataset. Their analysis compared a stratified Cox model with a Cox model which included cancer site as a random effect (frailty).

Both Cox models retained the same clinical (age, gender, WHO performance status and metastasis) and HRQOL (physical functioning, pain, appetite loss) parameters as being significant, yet the frailty model provides smaller confidence intervals. Further analyses are currently being performed to investigate trial and treatment as frailties in addition to cancer site as a frailty term. The application of these models to the analysis of survival data may open up new opportunities for the analysis of survival studies using QOL data.

View Poster

John Bean


 

[1] C. Quinten, F. Martinelli, C. Coens, J. Maringwa, C. Cleeland, H. Flecthner, C. Gotay, E. Greimel, M. King, D. Osoba, M.J.H. Taphoorn, B. Reeve, J. Ringash, J. Shmucker-Von Koch, J. Weis, A. Bottomley. Prognostic significance of patient heterogeneity in a dataset of 10,108 cancer patients. Quality of Life Research 19(1): 144, 2010.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023